Ferrari is an Italian sports car manufacturer based in Maranello, Italy. Enzo Ferrari founded the company in 1929 with the name Scuderia Ferrari. This company sponsored professional car drivers and manufactured professional race cars for 18 years before it added the function of producing street legal vehicles in 1947 under the name Ferrari S.P.A. However, it should be noted that throughout Ferrari's history, professional car racing has always been the company's top priority. In fact, the only reason that Ferrari began producing street legal cars was to earn money to continue funding the professional car racing division of the company in hard times. To further address funding problems, Ferrari sold part of the company to Fiat in 1969. Ferrari's favourite race is Formula One, where it has enjoyed success over long periods of time, particularly in the 1950s, 1960s, 1970s, late 1990s and 2000s. Enzo Ferrari controlled the racing division of the company until his death in 1988; he was 90 years old at the time of his death. Earlier that year, he launched the Ferrari F40, one of the most famous supercars ever made. Ferrari has an internally managed merchandising line that licenses many products bearing the Ferrari brand, including eyewear, pens, pencils, electronic goods, perfume, clothing, high-tech bicycles, cell phones and even laptop computers. Financial Times, a top international business newspaper, named Ferrari number-one on its 2007 list of the 100 Best Workplaces in Europe.

Mipharmaceuticals (MP) is a biology-based product-driven biopharmaceutical company that makes a class of therapeutics that selectively target enzymes within the Protein Kinase C (PKC) family. MP has leveraged this broad PKC platform to rapidly advance product candidates into human clinical trials with an initial clinical focus on therapies for acute cardiovascular disease and pain. Each compound in MP's pipeline represents a novel treatment approach in its therapeutic area, utilising first-in-class technology to target well validated disease mechanisms. The company's lead product, MP-9703, is designed to reduce injury associated with ischemia and reperfusion in the settings of acute myocardial infarction (AMI), stroke, renal transplant and other ischemic conditions. In a phase 2 clinical study in patients undergoing balloon angioplasty for the treatment of AMI, patients receiving MP-9703 experienced less damage to the heart muscle compared to patients receiving a placebo. MP-9703 has been granted Fast Track designation due to the significant unmet medical need for this indication. MP-1457, the company's development candidate for cytoprotection, completed a phase 1 trial in 2007, and MP-1578, the company's development candidate for inflammatory and neuropathic pain, completed a phase 1 clinical trial in October of 2008.